Identification

Name
Fenoldopam
Accession Number
DB00800  (APRD00969)
Type
Small Molecule
Groups
Approved
Description

A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [PubChem]

Structure
Thumb
Synonyms
  • Fénoldopam
  • Fenoldopam
  • Fenoldopamum
External IDs
SKF 82526 / SKF 82526-J
Product Ingredients
IngredientUNIICASInChI Key
Fenoldopam mesylateHA3R0MY01667227-57-0CVKUMNRCIJMVAR-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorlopamInjection, solution10 mg/mLIntravenousHospira, Inc.1997-09-232017-10-17Us
CorlopamInjection, solution10 mg/mLIntravenousHospira, Inc.1997-09-23Not applicableUs
Categories
UNII
INU8H2KAWG
CAS number
67227-56-9
Weight
Average: 305.756
Monoisotopic: 305.08187109
Chemical Formula
C16H16ClNO3
InChI Key
TVURRHSHRRELCG-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
IUPAC Name
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
SMILES
OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12

Pharmacology

Indication

For the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.

Structured Indications
Pharmacodynamics

Fenoldopam is an agonist at D1-like dopamine receptors, binds to α2-adrenoceptors, increasing renal blood flow.

Mechanism of action

Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α or β -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.

TargetActionsOrganism
AD(1B) dopamine receptor
agonist
Human
AD(1A) dopamine receptor
agonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptorNot AvailableHuman
UAlpha-1D adrenergic receptorNot AvailableHuman
UAlpha-1A adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Methylation, glucuronidation, and sulfation are the main routes of conjugation.

Route of elimination

Radiolabeled studies show that about 90% of infused fenoldopam is eliminated in urine, 10% in feces. Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Only 4% of the administered dose is excreted unchanged.

Half life

The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.

Clearance
Not Available
Toxicity

The most likely reaction of overdose would be excessive hypotension which should be treated with drug discontinuation and appropriate supportive measures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Fenoldopam.Experimental
AcebutololFenoldopam may increase the hypotensive activities of Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fenoldopam.Approved, Investigational
AliskirenFenoldopam may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololFenoldopam may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanFenoldopam may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineFenoldopam may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fenoldopam.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Fenoldopam.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fenoldopam.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Fenoldopam.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fenoldopam.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Fenoldopam.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fenoldopam.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fenoldopam.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Fenoldopam.Approved
AvanafilAvanafil may increase the antihypertensive activities of Fenoldopam.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Fenoldopam.Experimental
BarbitalBarbital may increase the hypotensive activities of Fenoldopam.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Fenoldopam.Approved
BenazeprilBenazepril may increase the hypotensive activities of Fenoldopam.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Fenoldopam.Withdrawn
BepridilFenoldopam may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Fenoldopam.Approved
BethanidineBethanidine may increase the hypotensive activities of Fenoldopam.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Fenoldopam.Experimental
BimatoprostFenoldopam may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Fenoldopam.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fenoldopam.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
BQ-123Fenoldopam may increase the hypotensive activities of BQ-123.Investigational
BretyliumFenoldopam may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Fenoldopam.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Fenoldopam.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fenoldopam.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenoldopam.Approved, Investigational
BupranololFenoldopam may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Fenoldopam.Experimental
CafedrineFenoldopam may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Canagliflozin.Approved
CandesartanFenoldopam may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Fenoldopam.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Fenoldopam.Experimental
CaptoprilFenoldopam may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fenoldopam.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Fenoldopam.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Fenoldopam.Approved
CarvedilolFenoldopam may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololFenoldopam may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideFenoldopam may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenoldopam.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Fenoldopam.Approved
CicletanineFenoldopam may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilFenoldopam may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fenoldopam.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fenoldopam.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoldopam.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Fenoldopam.Approved
CloranololFenoldopam may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fenoldopam.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fenoldopam.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Fenoldopam.Approved
CyclopenthiazideFenoldopam may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Fenoldopam.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dapagliflozin.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Fenoldopam.Approved, Investigational
DelaprilFenoldopam may increase the hypotensive activities of Delapril.Experimental
DeserpidineFenoldopam may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fenoldopam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Fenoldopam.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Diclofenamide.Approved
diethylnorspermineFenoldopam may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Fenoldopam.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Fenoldopam.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Dipyridamole.Approved
DorzolamideFenoldopam may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Fenoldopam.Approved
DuloxetineFenoldopam may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineFenoldopam may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
EnalaprilatFenoldopam may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Fenoldopam.Experimental
EpanololFenoldopam may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Eplerenone.Approved
EpoprostenolFenoldopam may increase the hypotensive activities of Epoprostenol.Approved
EprosartanFenoldopam may increase the hypotensive activities of Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Etacrynic acid.Approved
FelodipineFenoldopam may increase the hypotensive activities of Felodipine.Approved, Investigational
Ferulic acidFenoldopam may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Fimasartan.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Fenoldopam.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Fenoldopam.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Furosemide.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Fenoldopam.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Fenoldopam.Approved
GuanazodineFenoldopam may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFenoldopam may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
GuanoclorFenoldopam may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFenoldopam may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFenoldopam may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Fenoldopam.Experimental
HexamethoniumFenoldopam may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Fenoldopam.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Fenoldopam.Experimental
HydralazineHydralazine may increase the hypotensive activities of Fenoldopam.Approved
HydrochlorothiazideFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Fenoldopam.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Fenoldopam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imipramine.Approved
IndapamideFenoldopam may increase the hypotensive activities of Indapamide.Approved
IndenololFenoldopam may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Fenoldopam.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Fenoldopam.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Fenoldopam.Withdrawn
IrbesartanFenoldopam may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fenoldopam.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Fenoldopam.Approved
KetanserinKetanserin may increase the hypotensive activities of Fenoldopam.Investigational
LabetalolLabetalol may increase the hypotensive activities of Fenoldopam.Approved
LacidipineFenoldopam may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Levobupivacaine.Approved, Investigational
LevodopaFenoldopam may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Levosimendan.Approved, Investigational
LinsidomineFenoldopam may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Fenoldopam.Approved, Investigational
LofexidineFenoldopam may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Fenoldopam.Approved
MacitentanFenoldopam may increase the hypotensive activities of Macitentan.Approved
ManidipineFenoldopam may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Fenoldopam.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Fenoldopam.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fenoldopam.Approved
MethoserpidineFenoldopam may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Methyclothiazide.Approved
MethyldopaFenoldopam may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Fenoldopam.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fenoldopam.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fenoldopam.Approved
MetipranololFenoldopam may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Fenoldopam.Approved
MetoprololMetoprolol may increase the hypotensive activities of Fenoldopam.Approved, Investigational
MetyrosineFenoldopam may increase the hypotensive activities of Metyrosine.Approved
MibefradilFenoldopam may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Fenoldopam.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Fenoldopam.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Fenoldopam.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Fenoldopam.Approved
MoexiprilMoexipril may increase the hypotensive activities of Fenoldopam.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
MuzolimineFenoldopam may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nabilone.Approved, Investigational
NadololFenoldopam may increase the hypotensive activities of Nadolol.Approved
NaftopidilFenoldopam may increase the hypotensive activities of Naftopidil.Investigational
NebivololFenoldopam may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Fenoldopam.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Fenoldopam.Approved
NicorandilNicorandil may increase the hypotensive activities of Fenoldopam.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nifedipine.Approved
NiguldipineFenoldopam may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFenoldopam may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Fenoldopam.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Fenoldopam.Approved
NitrendipineFenoldopam may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Fenoldopam.Approved
ObinutuzumabFenoldopam may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Fenoldopam.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
OmapatrilatFenoldopam may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololFenoldopam may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Fenoldopam.Approved
PenbutololFenoldopam may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
PentoliniumFenoldopam may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fenoldopam.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Fenoldopam.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Fenoldopam.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Fenoldopam.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fenoldopam.Approved
PhenoxybenzamineFenoldopam may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fenoldopam.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Fenoldopam.Approved
PinacidilPinacidil may increase the hypotensive activities of Fenoldopam.Withdrawn
PindololFenoldopam may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pipamperone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Fenoldopam.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Fenoldopam.Withdrawn
Platelet Activating FactorFenoldopam may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideFenoldopam may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Fenoldopam.Approved
PrimidonePrimidone may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Fenoldopam.Approved
PropofolThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Fenoldopam.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Quetiapine.Approved
QuinaprilFenoldopam may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Fenoldopam.Approved
RamiprilRamipril may increase the hypotensive activities of Fenoldopam.Approved
RasagilineRasagiline may increase the hypotensive activities of Fenoldopam.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Fenoldopam.Approved
RescinnamineFenoldopam may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Fenoldopam.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Fenoldopam.Investigational
RiociguatFenoldopam may increase the hypotensive activities of Riociguat.Approved
RisperidoneFenoldopam may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFenoldopam may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Fenoldopam.Withdrawn
SaprisartanFenoldopam may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Fenoldopam.Approved, Investigational, Vet Approved
SelexipagFenoldopam may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
SitaxentanFenoldopam may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sotalol.Approved
SpiraprilFenoldopam may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
TalinololFenoldopam may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tamsulosin.Approved, Investigational
TelmisartanFenoldopam may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilFenoldopam may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Terazosin.Approved
TerlipressinFenoldopam may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineFenoldopam may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineFenoldopam may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thioridazine.Approved, Withdrawn
TiboloneFenoldopam may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenFenoldopam may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Fenoldopam.Approved
TizanidineThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tizanidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Fenoldopam.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tolcapone.Approved, Withdrawn
TolonidineFenoldopam may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Fenoldopam.Approved
TorasemideTorasemide may increase the hypotensive activities of Fenoldopam.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Fenoldopam.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fenoldopam.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Fenoldopam.Approved
TravoprostTravoprost may increase the hypotensive activities of Fenoldopam.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Fenoldopam.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Triamterene.Approved
TrichlormethiazideFenoldopam may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Fenoldopam.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Fenoldopam.Approved, Investigational
UnoprostoneFenoldopam may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Fenoldopam.Investigational
ValsartanValsartan may increase the hypotensive activities of Fenoldopam.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Fenoldopam.Approved
VerapamilThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Verapamil.Approved
VincamineFenoldopam may increase the hypotensive activities of Vincamine.Experimental
VinpocetineFenoldopam may increase the hypotensive activities of Vinpocetine.Investigational
XipamideFenoldopam may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFenoldopam may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Fenoldopam.Approved, Vet Approved
ZofenoprilFenoldopam may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference
US4197297
General References
Not Available
External Links
Human Metabolome Database
HMDB14938
KEGG Drug
D00613
KEGG Compound
C07693
PubChem Compound
3341
PubChem Substance
46504963
ChemSpider
3224
BindingDB
60917
ChEBI
5002
ChEMBL
CHEMBL588
Therapeutic Targets Database
DAP000254
PharmGKB
PA164784034
IUPHAR
939
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Wikipedia
Fenoldopam
ATC Codes
C01CA19 — Fenoldopam
FDA label
Download (239 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
2CompletedPreventionCardiac Surgical Procedures / Kidney Failure,Chronic / Kidney Failures, Acute1
2CompletedTreatmentCardiac Surgery With Cardiopulmonary Bypass1
2, 3Not Yet RecruitingPreventionAcute Kidney Injury (AKI) / Patent Ductus Arteriosus (PDA)1
3CompletedTreatmentAcute Renal Failure (ARF)1
3CompletedTreatmentKidney Failures, Acute1
3TerminatedPreventionAcute Renal Failure (ARF)1
4CompletedPreventionCardiac Complications / Cardiopulmonary Bypass1
4Unknown StatusTreatmentCoronary Artery Disease1
4WithdrawnTreatmentKidney Failures, Acute1
Not AvailableCompletedNot AvailableSalt-sensitive Hypertension1
Not AvailableTerminatedPreventionPartial Nephrectomy1

Pharmacoeconomics

Manufacturers
  • Hospira inc
  • Bedford laboratories
  • Pharmaforce inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous10 mg/mL
Prices
Unit descriptionCostUnit
Fenoldopam 10 mg/ml ampule213.75USD ml
Corlopam 10 mg/ml ampul81.9USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility4000 mg/LNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.272 mg/mLALOGPS
logP2.39ALOGPS
logP1.92ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.12ChemAxon
pKa (Strongest Basic)10.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7784
Caco-2 permeable-0.5345
P-glycoprotein substrateSubstrate0.8329
P-glycoprotein inhibitor INon-inhibitor0.9142
P-glycoprotein inhibitor IINon-inhibitor0.8567
Renal organic cation transporterNon-inhibitor0.6062
CYP450 2C9 substrateNon-substrate0.8216
CYP450 2D6 substrateNon-substrate0.7124
CYP450 3A4 substrateNon-substrate0.5301
CYP450 1A2 substrateNon-inhibitor0.713
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7436
Ames testNon AMES toxic0.7166
CarcinogenicityNon-carcinogens0.9006
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.7788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6864
hERG inhibition (predictor II)Inhibitor0.8833
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0429000000-b564c6e7915f2c21d65e

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Not Available
Direct Parent
Benzazepines
Alternative Parents
Azepines / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Aryl chlorides / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides
show 1 more
Substituents
Benzazepine / 1-hydroxy-2-unsubstituted benzenoid / Azepine / Aralkylamine / Phenol / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Azacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzazepine (CHEBI:5002)

Targets

Details
1. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728]
  4. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728]
  3. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:18